Results 171 to 180 of about 808,193 (291)

Developing countries have had enough: Is it time for a tobacco endgame?

open access: yesTobacco Induced Diseases, 2020
Joshua Kibet, Bornes C. Mosonik
doaj   +1 more source

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao   +24 more
wiley   +1 more source

Smoking Cessation Efforts [PDF]

open access: yesAcademic Emergency Medicine, 1995
openaire   +2 more sources

DADA Enhances CD8+ T Cell Stemness to Improve Anti‐Tumor Immunity and Immunotherapy Efficacy

open access: yesAdvanced Science, EarlyView.
Diisopropylamine dichloroacetate (DADA) enhances CD8+ T cell stemness by improving OXPHOS and mitochondrial fitness in a PDK1‐depenpendent manner. This metabolic shift strengthens CD8+ T cell anti‐tumor immunity, improves responses to PD‐1 blockade, and endows CAR‐T cells with prolonged persistence and resistance to terminal exhaustion, highlighting a ...
Mingyue Bi   +12 more
wiley   +1 more source

TRAP5 Inhibition Targeting Scar‐Associated Macrophages Ameliorates Acute Kidney Injury to Chronic Kidney Disease Transition

open access: yesAdvanced Science, EarlyView.
This study delineates macrophage heterogeneity along the acute kidney injury to chronic kidney disease transition. Single‐cell RNA sequencing reveals a TRAP5+ scar‐associated macrophage subset driven by Spp1–Cd44 signaling and mitochondrial metabolic reprogramming.
Chenxi Wang   +13 more
wiley   +1 more source

Gaps and Barriers Among Dental Undergraduates Towards Promoting and Assisting Tobacco Cessation: A Multicountry Cross-Sectional Study. [PDF]

open access: yesInt J Dent
Gopinath D   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy